Mednax, Inc (MD) Position Increased by Caisse DE Depot ET Placement DU Quebec
Caisse DE Depot ET Placement DU Quebec boosted its position in shares of Mednax, Inc (NYSE:MD) by 1,316.7% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 256,420 shares of the company’s stock after purchasing an additional 238,320 shares during the quarter. Caisse DE Depot ET Placement DU Quebec owned about 0.27% of Mednax worth $11,103,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently made changes to their positions in the stock. Thompson Siegel & Walmsley LLC boosted its holdings in shares of Mednax by 95.9% during the 2nd quarter. Thompson Siegel & Walmsley LLC now owns 2,170,741 shares of the company’s stock valued at $131,048,000 after acquiring an additional 1,062,584 shares during the last quarter. Balyasny Asset Management LLC boosted its holdings in shares of Mednax by 8,590.5% during the 2nd quarter. Balyasny Asset Management LLC now owns 1,060,247 shares of the company’s stock valued at $64,007,000 after acquiring an additional 1,048,047 shares during the last quarter. HealthCor Management L.P. purchased a new stake in shares of Mednax during the 2nd quarter valued at about $56,913,000. Toronto Dominion Bank boosted its holdings in shares of Mednax by 19,942.3% during the 3rd quarter. Toronto Dominion Bank now owns 723,928 shares of the company’s stock valued at $31,211,000 after acquiring an additional 720,316 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Mednax by 987.5% during the 3rd quarter. JPMorgan Chase & Co. now owns 756,215 shares of the company’s stock valued at $32,607,000 after acquiring an additional 686,678 shares during the last quarter. 98.48% of the stock is currently owned by institutional investors.
A number of analysts have recently issued reports on MD shares. Zacks Investment Research raised shares of Mednax from a “sell” rating to a “hold” rating in a report on Wednesday, October 11th. Robert W. Baird reiterated a “hold” rating and issued a $47.00 price objective on shares of Mednax in a research note on Sunday, September 3rd. KeyCorp set a $51.00 price objective on shares of Mednax and gave the stock a “buy” rating in a research note on Wednesday, November 1st. BMO Capital Markets started coverage on shares of Mednax in a research note on Monday, October 16th. They issued a “market perform” rating and a $46.00 price objective on the stock. Finally, Jefferies Group reiterated a “hold” rating and issued a $46.00 price objective on shares of Mednax in a research note on Tuesday, October 3rd. Two equities research analysts have rated the stock with a sell rating, ten have given a hold rating and two have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus price target of $54.50.
Mednax, Inc (MD) traded up $0.19 during midday trading on Friday, reaching $50.88. 801,500 shares of the company’s stock were exchanged, compared to its average volume of 1,095,293. Mednax, Inc has a 12 month low of $40.56 and a 12 month high of $72.13. The company has a market cap of $4,747.38, a PE ratio of 15.50, a price-to-earnings-growth ratio of 1.63 and a beta of 0.40. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.37 and a current ratio of 1.37.
Mednax (NYSE:MD) last released its earnings results on Wednesday, November 1st. The company reported $0.87 EPS for the quarter, hitting analysts’ consensus estimates of $0.87. Mednax had a net margin of 7.76% and a return on equity of 10.80%. The company had revenue of $868.95 million for the quarter, compared to analysts’ expectations of $864.78 million. During the same quarter last year, the business earned $1.09 EPS. The firm’s revenue was up 4.9% compared to the same quarter last year. sell-side analysts predict that Mednax, Inc will post 3.1 earnings per share for the current fiscal year.
In other news, Director Cesar L. Alvarez sold 10,668 shares of Mednax stock in a transaction that occurred on Friday, November 3rd. The shares were sold at an average price of $42.59, for a total transaction of $454,350.12. Following the sale, the director now owns 44,215 shares in the company, valued at $1,883,116.85. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider John C. Pepia sold 3,000 shares of Mednax stock in a transaction that occurred on Tuesday, September 12th. The shares were sold at an average price of $42.85, for a total transaction of $128,550.00. Following the sale, the insider now owns 35,569 shares in the company, valued at approximately $1,524,131.65. The disclosure for this sale can be found here. Company insiders own 2.40% of the company’s stock.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Want to see what other hedge funds are holding MD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mednax, Inc (NYSE:MD).
Receive News & Ratings for Mednax Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc and related companies with MarketBeat.com's FREE daily email newsletter.